Rigel Pharmaceuticals stock is traded at $45.71, with a volume of 553,297. It is down -10.88% in the last 24 hours and down -4.35% over the past month. Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
Previous Close:
$51.29
Open:
$51.53
24h Volume:
553,297
Relative Volume:
2.43
Market Cap:
$853.86M
Revenue:
$299.77M
Net Income/Loss:
$364.23M
P/E Ratio:
2.44
EPS:
$18.72
Net Cash Flow:
$79.27M
1W Performance:
-11.16%
1M Performance:
-4.35%
6M Performance:
+62.73%
1Y Performance:
+20.77%
1-Day Range:
$44.99$51.53
1-Week Range:
$44.99$51.84
52-Week Range:
$24.95$52.61
Rigel Pharmaceuticals Stock (RIGL) Company Profile
Name
Rigel PharmaceuticalsSector
HealthcareIndustry
BiotechnologyPhone
650-624-1100Address
611 GATEWAY BOULEVARD, SUITE 900, SOUTH SAN FRANCISCO, CA, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS